Characterization of Regulatory Sequences in Alternative Promoters of Hypermethylated Genes Associated with Tumor Resistance to Cisplatin

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2015 Mar 24

PMID 25798277

Authors

Mohammed A Ibrahim-Alobaide

Abdelsalam G Abdelsalam

Hytham Alobydi

Kakil Ibrahim Rasul

Ruiwen Zhang

Kalkunte S Srivenugopal

Affiliations

Soon will be listed here.

Abstract

The development of cisplatin resistance in human cancers is controlled by multiple genes and leads to therapeutic failure. Hypermethylation of specific gene promoters is a key event in clinical resistance to cisplatin. Although the usage of multiple promoters is frequent in the transcription of human genes, the role of alternative promoters and their regulatory sequences have not yet been investigated in cisplatin resistance genes. In a new approach, we hypothesized that human cancers exploit the specific transcription factor-binding sites (TFBS) and CpG islands (CGIs) located in the alternative promoters of certain genes to acquire platinum drug resistance. To provide a useful resource of regulatory elements associated with cisplatin resistance, we investigated the TFBS and CGIs in 48 alternative promoters of 14 hypermethylated cisplatin resistance genes previously reported. CGIs prone to methylation were identified in 28 alternative promoters of 11 hypermethylated genes. The majority of alternative promoters harboring CGIs (93%) were clustered in one phylogenetic subclass, whereas the ones lacking CGIs were distributed in two unrelated subclasses. Regulatory sequences, initiator and TATA-532 prevailed over TATA-8 and were found in all the promoters. B recognition element (BRE) sequences were present only in alternative promoters harboring CGIs, but CCAAT and TAACC were found in both types of alternative promoters, whereas downstream promoter element sequences were significantly less frequent. Therefore, it was hypothesized that BRE and CGI sequences co-localized in alternative promoters of cisplatin resistance genes may be used to design molecular markers for drug resistance. A more extensive knowledge of alternative promoters and their regulatory elements in clinical resistance to cisplatin is likely to usher novel avenues for sensitizing human cancers to treatment.

References

Cocozza S, Scala G, Miele G, Castaldo I, Monticelli A . A distinct group of CpG islands shows differential DNA methylation between replicas of the same cell line in vitro. BMC Genomics. 2013; 14:692. PMC: 4008136. DOI: 10.1186/1471-2164-14-692. View

Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. DOI: 10.1038/nrc2167. View

Xin D, Hu L, Kong X . Alternative promoters influence alternative splicing at the genomic level. PLoS One. 2008; 3(6):e2377. PMC: 2409967. DOI: 10.1371/journal.pone.0002377. View

Batut P, Dobin A, Plessy C, Carninci P, Gingeras T . High-fidelity promoter profiling reveals widespread alternative promoter usage and transposon-driven developmental gene expression. Genome Res. 2012; 23(1):169-80. PMC: 3530677. DOI: 10.1101/gr.139618.112. View

Tanaka T, Bai T, Toujima S, Utsunomiya T, Matsuoka T, Kobayashi A . Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells. Oncol Rep. 2012; 27(4):1292-8. PMC: 3583479. DOI: 10.3892/or.2012.1628. View

Vavouri T, Elgar G . Prediction of cis-regulatory elements using binding site matrices--the successes, the failures and the reasons for both. Curr Opin Genet Dev. 2005; 15(4):395-402. DOI: 10.1016/j.gde.2005.05.002. View

Cusanovich D, Pavlovic B, Pritchard J, Gilad Y . The functional consequences of variation in transcription factor binding. PLoS Genet. 2014; 10(3):e1004226. PMC: 3945204. DOI: 10.1371/journal.pgen.1004226. View

Forrest A, Kawaji H, Rehli M, Baillie J, de Hoon M, Haberle V . A promoter-level mammalian expression atlas. Nature. 2014; 507(7493):462-70. PMC: 4529748. DOI: 10.1038/nature13182. View

Yang D, Okamoto K . Structural insights into G-quadruplexes: towards new anticancer drugs. Future Med Chem. 2010; 2(4):619-46. PMC: 2886307. DOI: 10.4155/fmc.09.172. View

10.

Jeziorska D, Jordan K, Vance K . A systems biology approach to understanding cis-regulatory module function. Semin Cell Dev Biol. 2009; 20(7):856-62. DOI: 10.1016/j.semcdb.2009.07.007. View

11.

Hackenberg M, Barturen G, Carpena P, Luque-Escamilla P, Previti C, Oliver J . Prediction of CpG-island function: CpG clustering vs. sliding-window methods. BMC Genomics. 2010; 11:327. PMC: 2887419. DOI: 10.1186/1471-2164-11-327. View

12.

Meng H, Wang J, Xiong Z, Xu F, Zhao G, Wang Y . Quantitative design of regulatory elements based on high-precision strength prediction using artificial neural network. PLoS One. 2013; 8(4):e60288. PMC: 3613377. DOI: 10.1371/journal.pone.0060288. View

13.

Maston G, Zhu L, Chamberlain L, Lin L, Fang M, Green M . Non-canonical TAF complexes regulate active promoters in human embryonic stem cells. Elife. 2012; 1:e00068. PMC: 3490149. DOI: 10.7554/eLife.00068. View

14.

Hudson J, Brooks S, Graves D . Interactions of actinomycin D with human telomeric G-quadruplex DNA. Biochemistry. 2009; 48(21):4440-7. PMC: 3021945. DOI: 10.1021/bi900203z. View

15.

Jacox E, Gotea V, Ovcharenko I, Elnitski L . Tissue-specific and ubiquitous expression patterns from alternative promoters of human genes. PLoS One. 2010; 5(8):e12274. PMC: 2923625. DOI: 10.1371/journal.pone.0012274. View

16.

Zhao Z, Han L . CpG islands: algorithms and applications in methylation studies. Biochem Biophys Res Commun. 2009; 382(4):643-5. PMC: 2679166. DOI: 10.1016/j.bbrc.2009.03.076. View

17.

Martinez E . Core promoter-selective coregulators of transcription by RNA polymerase II. Transcription. 2012; 3(6):295-9. PMC: 3630184. DOI: 10.4161/trns.21846. View

18.

Han L, Zhao Z . CpG islands or CpG clusters: how to identify functional GC-rich regions in a genome?. BMC Bioinformatics. 2009; 10:65. PMC: 2652441. DOI: 10.1186/1471-2105-10-65. View

19.

Guo R, Wu G, Li H, Qian P, Han J, Pan F . Promoter methylation profiles between human lung adenocarcinoma multidrug resistant A549/cisplatin (A549/DDP) cells and its progenitor A549 cells. Biol Pharm Bull. 2013; 36(8):1310-6. DOI: 10.1248/bpb.b13-00153. View

20.

Rabik C, Dolan M . Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2006; 33(1):9-23. PMC: 1855222. DOI: 10.1016/j.ctrv.2006.09.006. View